What is the role of mesenchymal stem cell injection in chronic lung graft‑versus‑host disease (cGVHD) bronchiolitis obliterans syndrome (BOS)?

Mesenchymal Stem Cell Therapy for Chronic Lung GVHD BOS: An Emerging but Not Guideline-Endorsed Option

Mesenchymal stem cell (MSC) injection is not currently recommended by established guidelines for chronic lung GVHD bronchiolitis obliterans syndrome (BOS), but emerging research suggests it may offer a safe and potentially effective salvage therapy option for steroid-refractory cases when standard treatments have failed.

Current Guideline-Based Management

The 2020 NCCN guidelines do not mention MSC therapy as a treatment option for BOS 1. Instead, the established approach for lung cGVHD/BOS includes:

First-Line Treatment

• Inhaled steroids (budesonide or fluticasone) plus azithromycin (FAM regimen: fluticasone, azithromycin, and montelukast) 1
• Systemic corticosteroids (0.5-1 mg/kg/day) 1
• Critical caveat: Azithromycin should only be used for BOS treatment, NOT prophylaxis, due to increased cancer relapse risk 1

Second-Line Options for Steroid-Refractory Disease

The guidelines note that lung cGVHD responds poorly to most systemic therapies 1:

• Etanercept: Shows some efficacy specifically for BOS with 32% response rate (defined as ≥10% improvement in FEV1), though this is modest 1
• Extracorporeal photopheresis (ECP): Only 15% response rate for lung involvement—significantly lower than other organs 1
• Rituximab: Only 30% response rate for lung cGVHD 1
• Ruxolitinib: Only 10% response rate for lung involvement 1
• Ibrutinib: FDA-approved for steroid-refractory cGVHD but lung-specific efficacy data limited 1

The guidelines emphasize that lung transplantation should be evaluated for progressive or worsening lung cGVHD after 2-3 lines of therapy 1.

Emerging MSC Evidence

While not guideline-endorsed, recent research provides compelling data on MSC therapy:

Most Robust Evidence

The 2019 multicenter prospective cohort study (n=81) represents the highest-quality evidence 2:

• 71% response rate in MSC group vs 44% in control group (p=0.013)
• Significantly better FEV1 rate of decline improvement (53 mL/month difference, p=0.040)
• 3-year overall survival: 70.6% (MSC) vs 58.2% (control), though not statistically significant (p=0.21)
• No increased infection or leukemia relapse rates
• Mechanism: Increased IL-10-producing CD5+ B cells (anti-inflammatory pathway)

Pediatric Data

A 2023 single-arm trial in 4 pediatric patients showed 3:

• 75% partial response rate (3/4 patients)
• Safe administration with no treatment-related adverse events
• All patients alive at median 19-month follow-up with no lung transplant indication
• Dose: 1×10⁶ cells/kg, single injection

Additional Supporting Evidence

• 2024 study: Repeated MSC infusions (4 doses over 8 weeks) showed 60% overall response rate with 80% overall survival 4
• 2022 study: Low-dose MSCs (0.5-1×10⁶/kg) stabilized lung function decline in lung transplant recipients with chronic allograft dysfunction 5

Clinical Algorithm for MSC Consideration

When to Consider MSC Therapy:

1. Patient has steroid-refractory BOS (meeting NIH criteria for steroid-refractory cGVHD 1)
2. Failed at least 2-3 standard therapies including:
   • FAM regimen
   • Systemic corticosteroids
   • At least one second-line agent (etanercept, ruxolitinib, ibrutinib, or ECP)
3. Not yet a lung transplant candidate or awaiting transplant evaluation
4. No active uncontrolled infection (though manageable infections post-MSC appear tolerable 3)

Practical Implementation:

• Dose: 1×10⁶ cells/kg intravenously 3, 2
• Frequency: Consider repeated infusions every 2 weeks for 4 doses based on 2024 data 4, though single dose showed efficacy in 2019 study 2
• Source: Bone marrow or adipose tissue-derived MSCs both show efficacy 3, 2, 4
• Monitoring: FEV1 at baseline, 3,6, and 12 months; steroid dose reduction; quality of life measures

Critical Caveats and Pitfalls

1. MSC therapy is investigational: Not FDA-approved for BOS; should ideally be administered within clinical trial context 1
2. Infection risk remains: While MSCs don't increase infection rates statistically, patients with advanced BOS have high baseline infection risk (81.8% hospitalization rate for respiratory infections in one series 6)
3. Steroid-induced complications: Many BOS patients have severe steroid toxicity (osteoporosis, myopathy) 3; MSC's steroid-sparing effect is a major benefit
4. Response definition variability: "Partial response" can mean FEV1 stabilization rather than improvement—still clinically meaningful in progressive disease 2, 5
5. Timing matters: Earlier intervention may be more effective; median time from HSCT to BOS diagnosis is typically 24 months 6

Practical Recommendation

For steroid-refractory BOS after failing standard therapies, MSC therapy represents a reasonable salvage option with strong safety profile and emerging efficacy data 2. The 71% response rate significantly exceeds that of guideline-mentioned therapies for lung cGVHD (10-32% range) 1. However, this should be pursued within a clinical trial framework when possible, or as compassionate use when standard options are exhausted and before lung function deteriorates to transplant-only territory. The steroid-sparing effect alone may improve quality of life and reduce infection risk in this vulnerable population.